New Weight Loss Pill Foundayo Approved in the UK

What is orforglipron?#

Orforglipron is a new weight loss and type 2 diabetes medication developed by Eli Lilly. It's sold under the brand name Foundayo, and it works on the same GLP-1 pathway as Wegovy, Ozempic and Mounjaro, but you take it as a tablet rather than an injection.

It was approved by the US Food and Drug Administration (FDA) in April 2026, and has now also been approved by the MHRA in the UK, making it the first oral GLP-1 receptor agonist with no food or water restrictions to receive UK regulatory approval. The approval followed a large trial programme called ATTAIN, which included over 3,127 participants in ATTAIN-1 alone, across people with obesity and type 2 diabetes.

If you've been keeping an eye on GLP-1 medications, you'll already know these drugs have changed how weight management is approached in the UK. Orforglipron is interesting because it's a small molecule rather than a peptide, which means it can be made into a stable tablet that doesn't need refrigeration and, unlike some other oral GLP-1s, doesn't come with strict food or water restrictions.

How does orforglipron work?#

Orforglipron mimics GLP-1, a hormone your gut releases naturally after eating. It binds to GLP-1 receptors in the pancreas, stomach and brain, and this triggers a few useful effects:

• Your pancreas releases more insulin when blood sugar is high, which helps control glucose levels in type 2 diabetes
• Your stomach empties more slowly, so you feel fuller for longer after meals
• Appetite signals in the brain are dampened, reducing hunger and cravings

The net effect is that most people eat less without having to fight constant hunger, and blood sugar control improves. Like all GLP-1 medications, it works best alongside a reduced-calorie diet and regular activity, not as a standalone fix.

How is orforglipron taken and dosed?#

One of orforglipron's selling points is flexibility. You take one tablet a day, at any time, with or without food or water. That's a genuine difference from the Wegovy tablet, which has to be taken on an empty stomach with no more than 120ml of water and a 30-minute wait before eating, drinking anything else, or taking other oral medicines.

The approved Foundayo dosing schedule starts low and increases with a minimum of one month at each level:

• 0.8mg (starting dose)
• 2.5mg
• 5.5mg
• 9mg
• 14.5mg
• 17.2mg (maximum dose)

Not everyone needs to reach the top dose. Clinicians typically titrate upward based on how well someone tolerates the medication and their response.

What did the clinical trials show?#

Weight loss results#

The headline figure from the phase 3 ATTAIN trials is that people taking the maximum 17.2mg dose lost an average of around 11% of their body weight over 72 weeks. An earlier phase 3 dataset, measured at 40 weeks, showed 7.9% average weight loss (around 7.3kg), alongside a 1.5% reduction in HbA1c.

Earlier phase 2 data, from a smaller group of participants, showed even higher percentages at certain doses: between 9.4% and 14.7% average weight loss by week 36, compared with just 2.3% in the placebo group. Trial results vary depending on dose, duration and the specific population studied, which is normal for GLP-1 research.

Type 2 diabetes results#

For blood sugar control, orforglipron performed well against both placebo and an existing injectable GLP-1 (dulaglutide). In one phase 2 study, HbA1c dropped by 2.1% with orforglipron compared with 1.1% with dulaglutide and 0.4% with placebo over 26 weeks. Average weight loss in the same study was 10.1kg with orforglipron versus 3.9kg with dulaglutide.

These numbers put orforglipron in a similar range to injectable GLP-1s already used in NHS type 2 diabetes care, though head-to-head UK data doesn't exist yet.

Is Foundayo the Mounjaro pill?#

Worth clearing up a common mix-up: orforglipron is not simply "Mounjaro in tablet form." Both are made by Eli Lilly, but they act on different receptors and have separate trial programmes. Mounjaro (tirzepatide) acts on both GIP and GLP-1 receptors and is given as a weekly injection, while orforglipron acts only on GLP-1 receptors and is taken as a daily tablet. They are distinct medications with different mechanisms, dosing schedules and trial results.

Who might not be suitable for orforglipron?#

The full UK Summary of Product Characteristics (SmPC) for Foundayo is due to be published shortly following MHRA approval. That document will set out the confirmed contraindications and precautions for orforglipron specifically. Until then, it's not appropriate to rely on exclusion criteria from other GLP-1 medications as a substitute.

Anyone considering GLP-1 treatment — orforglipron or otherwise — needs a proper clinical assessment first, including a review of other medications they're taking, since GLP-1s can interact with insulin, sulfonylureas, and warfarin, among other drugs.

Side effects and considerations#

The MHRA has confirmed the following as the most common side effects for orforglipron:

• Nausea
• Constipation
• Diarrhoea
• Vomiting
• Dyspepsia
• Abdominal pain

These tend to be worse when starting the medication or stepping up a dose, and usually settle over a few weeks. More serious but less common effects reported included severe abdominal pain and dehydration from persistent vomiting or diarrhoea, which is why dose increases are staged slowly and why medical supervision matters.

How does orforglipron compare to other GLP-1 treatments?#

Here's a rough comparison based on the clinical trial data published so far. Trial designs differ, so treat this as a general guide rather than a like-for-like comparison.

A few things stand out. The Wegovy pill, already approved in the UK by the MHRA and available through services like Totiva's weight loss treatment page, currently shows stronger weight loss results in trials than orforglipron, though it requires stricter dosing rules (empty stomach, limited water, 30-minute food gap). Orforglipron's advantage is convenience: no injection, no food timing, no water restriction.

Mounjaro (tirzepatide) still leads on raw weight loss percentage in most published data, but it works on two hormone pathways (GIP and GLP-1) rather than one, and it's an injection, not a tablet, so it's not a direct comparison for people specifically looking for oral options.

What happens next in the UK?#

Now that the MHRA has granted its licence, Foundayo is licensed in the UK, with launch, availability and pricing still to be confirmed. The next step will be a NICE assessment of whether it should be funded on the NHS, weighing up cost-effectiveness against existing options like semaglutide and tirzepatide. The MHRA has confirmed Foundayo is not currently available via the NHS. NICE's current guidance for adults with obesity generally centres on a BMI of 30+ (or 27+ with a weight-related health condition such as type 2 diabetes or high blood pressure), and any future NHS pathway for orforglipron would likely follow similar thresholds, alongside NHS Tier 3 specialist weight management service criteria for the highest-need patients.

NHS funding decisions for newly approved GLP-1 drugs have historically taken considerably longer than the initial licensing step. Keep an eye on updates from Totiva as more information about availability and pricing is confirmed.

What might it cost in the UK?#

UK pricing for Foundayo has not yet been confirmed. Any figures circulating online should be treated with caution until Eli Lilly or a licensed UK pharmacy publishes official pricing.

Be wary of anyone selling unverified versions online#

Even though orforglipron now has MHRA approval, it's worth being clear: GLP-1 medicines are prescription-only and must be obtained from a registered pharmacy with a prescription. The MHRA has repeatedly warned about counterfeit GLP-1 products sold through unregulated websites and social media, some of which have caused serious harm. If you're buying from an unregistered source, there's no way to verify what's actually in the product.

The bottom line#

Orforglipron (Foundayo) has now been approved by the MHRA, making it a licensed option in the UK. It's a once-daily pill with solid trial results and none of the food or water restrictions that come with the existing Wegovy tablet. Launch, commercial availability and pricing are still to be confirmed. If you're interested in weight management support in the meantime, Totiva offers a weight loss service reviewed by UK clinicians. You can explore your options to find out more.